MDT

96.87

+0.54%↑

146.9

-0.44%↓

VEEV

230.21

-2.17%↓

HQY

83.08

-3.5%↓

PHR.US

16.31

-4.06%↓

MDT

96.87

+0.54%↑

146.9

-0.44%↓

VEEV

230.21

-2.17%↓

HQY

83.08

-3.5%↓

PHR.US

16.31

-4.06%↓

MDT

96.87

+0.54%↑

146.9

-0.44%↓

VEEV

230.21

-2.17%↓

HQY

83.08

-3.5%↓

PHR.US

16.31

-4.06%↓

MDT

96.87

+0.54%↑

146.9

-0.44%↓

VEEV

230.21

-2.17%↓

HQY

83.08

-3.5%↓

PHR.US

16.31

-4.06%↓

MDT

96.87

+0.54%↑

146.9

-0.44%↓

VEEV

230.21

-2.17%↓

HQY

83.08

-3.5%↓

PHR.US

16.31

-4.06%↓

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Avatud

SektorTervishoid

1.05

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.03

Max

1.07

Põhinäitajad
By Trading Economics
Sissetulek	1.8M -32M
Müük	-166K 1.7M
Kasumimarginaal	-1,852.384
Töötajad	181
EBITDA	7.9M -29M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+337.74% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	3. märts 2026

Turustatistika
By TradingEconomics
Turukapital	-9.2M 117M
Eelmine avamishind	1.05
Eelmine sulgemishind	1.05

Uudiste sentiment

By Acuity

10%

90%

10 / 370 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. jaan 2026, 23:54 UTC

Market Talk

CBA Could Underperform Again in 2026 -- Market Talk

12. jaan 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12. jaan 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

12. jaan 2026, 23:43 UTC

Market Talk

Gold Edges Lower on Likely Technical Correction -- Market Talk

12. jaan 2026, 23:18 UTC

Omandamised, ülevõtmised, äriostud

Paramount Sues Warner Bros., Plans Proxy Fight. The Ellisons Aren't Giving Up. -- Barrons.com

12. jaan 2026, 21:56 UTC

Market Talk

Light & Wonder Gets Positive Outcome From Lawsuit -- Market Talk

12. jaan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. jaan 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

12. jaan 2026, 21:50 UTC

Market Talk

Tulu

Auto & Transport Roundup: Market Talk

12. jaan 2026, 21:18 UTC

Market Talk

Global Equities Roundup: Market Talk

12. jaan 2026, 21:18 UTC

Market Talk

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

12. jaan 2026, 20:54 UTC

Tulu

Gap, Fortinet, and More Stocks That Usually Outperform After Earnings -- Barrons.com

12. jaan 2026, 20:48 UTC

Market Talk

Oil Futures Settle Higher in Choppy Trade -- Market Talk

12. jaan 2026, 20:33 UTC

Market Talk

U.S. Natural Gas Jumps on Colder Weather Outlook -- Market Talk

12. jaan 2026, 20:18 UTC

Omandamised, ülevõtmised, äriostud

Credit Agricole Sees Banco BPM Stake Helping 2025 Net by EUR200M >ACA.FR

12. jaan 2026, 20:18 UTC

Omandamised, ülevõtmised, äriostud

Credit Agricole: European Central Bank Approves Crossing of 20% Threshold in Share Capital of Banco BPM

12. jaan 2026, 19:39 UTC

Market Talk

J&J CEO: Trump Pact Allows Company to Focus on Core Operations -- Market Talk

12. jaan 2026, 19:36 UTC

Market Talk

Gold and Silver Set New Records on Fed Probe -- Market Talk

12. jaan 2026, 19:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12. jaan 2026, 19:33 UTC

Market Talk

Venezuela's 'Proven' Oil Reserves Raises Questions -- Market Talk

12. jaan 2026, 19:24 UTC

Omandamised, ülevõtmised, äriostud

Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23

12. jaan 2026, 19:22 UTC

Omandamised, ülevõtmised, äriostud

Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'

12. jaan 2026, 18:21 UTC

Omandamised, ülevõtmised, äriostud

Paramount Plans Proxy Fight to Push Hostile Warner Bid -- 2nd Update

12. jaan 2026, 18:20 UTC

Omandamised, ülevõtmised, äriostud

This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest. -- Barrons.com

12. jaan 2026, 18:19 UTC

Market Talk

Modest Canadian Economic Impact Seen from Venezuela Changes -- Market Talk

12. jaan 2026, 18:16 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Comcast Could Unlock Value With a Spinoff of NBCUniversal Assets, Analysts Say -- Market Talk

12. jaan 2026, 18:09 UTC

Market Talk

Global Equities Roundup: Market Talk

12. jaan 2026, 18:09 UTC

Market Talk

Baidu's Outlook Bodes Well For Shares -- Market Talk

12. jaan 2026, 18:01 UTC

Omandamised, ülevõtmised, äriostud

QXO Is Raising Another $1.8 Billion for Its M&A War Chest -- Barrons.com

12. jaan 2026, 18:00 UTC

Market Talk

Canada's 'Breakeven' Employment Recalibrating -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

337.74% tõus

12 kuu keskmine prognoos

Keskmine 4.64 USD 337.74%

Kõrge 8 USD

Madal 2 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

9 ratings

Osta

Hoia

Müü

Põhineb 9 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

10 / 370 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.